Genomics

Many diseases can be prevented if genetic risk is identified early enough.

Genomics harnesses large-scale DNA data to generate accurate personalised health risk profiles for a range of common diseases, enabling proactive interventions and better patient outcomes, and accelerating drug discovery.

Founded in 2014 by four leading Oxford professors – Peter Donnelly (CEO), Gil McVean, Gerton Lunter and Chris Spencer – the company is pioneering a future where medicine is predictive, preventative and personal, and is backed by global commercial partnerships across the UK and US.